Fertility, Hypercoagulability, and Inflammation (FREYA) Registry
NCT ID: NCT04537416
Last Updated: 2025-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1000 participants
OBSERVATIONAL
2018-04-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, we will evaluate the frequency of thrombophilia as a cause of recurrent pregnancy loss and provide insights into our patient care experience at BWH.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EFFects of Thrombophilia on the Outcomes of Assisted Reproduction Technologies
NCT02407730
Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score
NCT03336463
Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome
NCT06918236
The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
NCT02990403
Pregnancy and Fibrinogen Disorders
NCT03920332
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Over a 2-year period, we will perform a retrospective observational cohort analysis of 1000 patients referred to the BWH Center for Infertility and Reproductive Surgery for evaluation of recurrent pregnancy loss. This cohort will include a retrospective analysis of 200 infertility patients referred to Dr. Piazza's Cardiovascular Medicine clinic for evaluation of thrombophilia.
We will also enroll prospectively for 18 months patients referred to the BWH Center for Infertility and Reproductive Surgery for evaluation of recurrent pregnancy loss.
Study Population:
We will include a study population that is representative of the ethnic and racial diversity of women who receive care at BWH. We will not enroll post-menopausal women, men or children because recurrent pregnancy loss specifically affects women of child-bearing potential. We do not plan to enroll pregnant women because we are specifically focused on women with recurrent pregnancy loss presenting for assisted reproductive therapy.
Retrospective Cohort:
For our retrospective analysis we will include 800 consecutive women at least 18 years old but not greater than 40 years old with a chief complaint of recurrent pregnancy loss referred to the BWH Center for Infertility and Reproductive Surgery and 200 consecutive patients referred to Dr. Piazza's Cardiovascular Medicine clinic for evaluation of thrombophilia as a cause of recurrent pregnancy loss. This will provide a total of 1000 patients for the retrospective cohort analysis.
Study Inclusion Criteria
1. Age 18-40 years
2. 2 or more pregnancy losses (including chemical pregnancies but not ectopic pregnancy)
3. Evaluated at the BWH Center for Infertility and Reproductive Surgery or the Watkins Cardiovascular Clinic
Study Exclusion Criteria
1. Infertility due to uterine factors (such as Asherman's Syndrome)
2. Known translocation carrier
3. Prior venous thromboembolism on anticoagulation
4. Abnormal uterine cavity on hysterosalpingogram/hysteroscopy
Prospective Cohort:
For the 18-month prospective cohort analysis, we will enroll consecutive patients evaluated at the BWH Center for Infertility and Reproductive Surgery for recurrent pregnancy loss.
Study Inclusion Criteria
1. Age 18-40 years
2. 2 or more pregnancy losses (including chemical pregnancies but not ectopic pregnancy)
3. Evaluated at the BWH Center for Infertility and Reproductive Surgery
Study Exclusion Criteria
1. Infertility due to uterine factors (such as Asherman's Syndrome)
2. Known translocation carrier
3. Prior venous thromboembolism on anticoagulation
4. Abnormal uterine cavity on hysterosalpingogram/hysteroscopy
Study Procedures:
From the EPIC Electronic Health Record (EHR), we will record demographic characteristics, comorbid conditions, details about the presentation of infertility, pregnancy losses, and prior assisted reproductive treatments, thrombophilia panel results, treatments, and outcomes, including successful pregnancies and deliveries. We will calculate the prevalence of thrombophilia in patients referred to BWH Center for Infertility and Reproductive Surgery for evaluation of recurrent pregnancy loss. We will describe the outcomes of patients receiving prophylactic low-dose anticoagulation, including bleeding, thrombotic events, and live births. We will perform multivariable regression analyses to answer additional key questions of predictors of thrombophilia as a cause of recurrent pregnancy loss and successful treatment of infertility due to thrombophilia.
The proposed retrospective and prospective cohort analysis will provide information about the standard of care at BWH for patients with recurrent pregnancy loss who may have thrombophilia. The registry will not change the standard of care for diagnosis and treatment of the patients at BWH in any way. The registry will not mandate any testing or treatments. There will be no required study visits, follow-up, or subject or provider contact.
Data Analysis Plan:
We will describe the results of patients receiving prophylactic anticoagulation, including frequency of bleeding and thrombotic events. We will calculate the prevalence of thrombophilia in patients referred to BWH Center for Infertility and Reproductive Surgery for evaluation of recurrent pregnancy loss. We will perform multivariable regression analyses to answer additional key questions of predictors of thrombophilia as a cause of recurrent pregnancy loss, chemical pregnancy after assisted reproductive therapy, and successful treatment of infertility due to thrombophilia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Women with recurrent pregnancy loss
consecutive women at least 18 years old but not greater than 40 years old with a chief complaint of recurrent pregnancy loss
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 2 or more pregnancy losses (including chemical pregnancies but not ectopic pregnancy)
3. Evaluated at the BWH Center for Infertility and Reproductive Surgery or the Watkins Cardiovascular Clinic
Exclusion Criteria
2. Known translocation carrier
3. Prior venous thromboembolism on anticoagulation
4. Abnormal uterine cavity on hysterosalpingogram/hysteroscopy
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gregory Piazza, MD, MS
Associate Director, Thrombosis Research Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017P001215/PHS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.